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Background. Many Type 2 diabetes (T2DM) patients in Korea take Korean Red Ginseng (KRG) for various reasons. In this study,
we investigated the effects of KRG administration on diabetic peripheral neuropathy in T2DM patients.Methods. This study was a
randomized, double-blind, placebo-controlled trial. Participants were randomly allocated to either the placebo or KRG group and
took corresponding tablets for 24 weeks. The primary outcomes were changes in current perception threshold (CPT) at week 24.
Secondary outcomes were altered fasting plasma glucose, HbA1c, and various metabolic and inflammatory markers at week 24.
Results. Sixty-one patients completed the study. The CPT of the lower extremities at various frequencies exhibited significant
improvements at week 24 in the KRG group. Other metabolic parameters were not altered after 24 weeks in both groups. In the
subgroup analysis, CPT levels were improved in those with a longer diabetes duration or who already had neuropathy at the
beginning of the study, and insulin resistance was improved in patients with a shorter diabetes duration. Conclusion. Twenty-
four week administration of KRG in T2DM patients resulted in a significant improvement in neuropathy, especially in those
with a longer diabetes duration. A further, larger population study with a longer follow-up period is warranted to verify the
effects of KRG on diabetic neuropathy.
1. Introduction
Type 2 diabetes is the fastest-growing metabolic disease in
the world, which involves various organs [1]. Chronic hyper-
glycemia leads to a damage in small blood vessels in periph-
eral nerves, kidney, and retina as well as in larger blood
vessels of the heart and the brain. These chronic diabetic
microvascular and macrovascular complications lead to sig-
nificant mortality and morbidity in diabetes patients. Among
them, diabetic neuropathy is the most common microvascu-
lar complication affecting as many as 50% of diabetes
patients, and it is the leading cause of nontraumatic limb
amputation [2–4].
Measurement of current perception threshold (CPT)
using the Neurometer® has been proven to be a reliable
method to assess diabetic neuropathy by quantifying sensory
fiber function. The CPT test is widely used in clinical practice
for being noninvasive and being able to detect not only
advanced severe neuropathy but also early asymptomatic
neuropathy compared to other sensory tests [5–7]. Despite
many experimental and clinical studies, there is no effective
treatment that directly affects the pathogenesis of diabetic
neuropathy. We use α-lipoic acid to reduce oxygen free rad-
icals, and anticonvulsants such as gabapentin and pregabalin
for pain relief in painful neuropathy, but their effectiveness
and persistence are limited [2, 8, 9].
Ginseng (Panax ginseng Meyer) roots have been widely
used as an herbal treatment in East Asia for more than
2000 years. Korean Red Ginseng (KRG) is a popular tradi-
tional herb that is known to have beneficial effects in
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obesity, postmenopausal symptoms, cholesterol levels, and
cardiovascular diseases. There are several animal and human
studies to support these effects [10, 11]. Many Type 2
diabetes patients also take KRG as a complementary
and alternative medicine for better glycemic control and
health promotion [12]. Various animal and clinical stud-
ies have been conducted, and KRG has been shown to
improve postprandial glucose and insulin sensitivity in sev-
eral studies [13, 14].
Such effects of KRG are thought to be due to anti-
inflammatory and antioxidant activities [15–17]. Chronic
hyperglycemia with consequent oxidative stress, advanced
glycation end product (AGE), and various inflammatory
responses are known to mediate diabetic complications. Sev-
eral animal studies have demonstrated that Red Ginseng can
reduce diabetic microvascular complications and brain neu-
ronal damage by reducing oxidative stress and advanced gly-
cation end products (AGE) [18–20].
However, human studies on the effects of Red Ginseng
on diabetic complications are lacking and the follow-up
period is short. In this study, we investigated the effects
of KRG administration on diabetic neuropathy in Type 2
diabetes patients.
2. Research Design and Methods
2.1. Subjects. A total of 70 Type 2 diabetes patients who vis-
ited the Gangnam Severance Hospital between April 2016
and July 2017 were enrolled in this single-center, double-
blind, randomized, placebo controlled trial. Eligible patients
were men and women between the ages of 19 and 75 who
were diagnosed with Type 2 diabetes more than 6 months
prior and those taking oral antidiabetic agents at the time
of enrollment with an unchanged dose or type of drug within
the last 3 months. Patients with HbA1c > 10%, eGFR < 30
ml/min/1:73m2, AST/ALT > 3 times greater the upper nor-
mal limit, taking glucocorticoids or any herbal medicine
within the past 3 months, chronic inflammatory disease in
the active phase or acute infection status, and pregnant or
lactating were excluded. Enrolled subjects were randomized
using a computer-generated randomization table.
2.2. Design. Subjects were randomized to receive KRG extract
tablets or placebos for 24 weeks. They were instructed to take
2 KRG extract tablets, with each tablet containing 500 milli-
grams of KRG extract powder, which is equivalent to taking
3 g of KRG extract per day. The components of KRG are as
follows: 0.37mg/g of ginsenoside Rg1, 0.49mg/g of ginseno-
side Re, 1.23mg/g of ginsenoside Rf, 2.35mg/g of ginsenoside
Rh1, 3.06mg/g of ginsenoside Rg2s, 4.43mg/g of ginsenoside
Rb1, 2.01mg/g of ginsenoside Rc, 1.71mg/g of ginsenoside
Rb2, 0.86mg/g of ginsenoside Rd, 3.27mg/g of ginsenoside
Rg3s, 1.02mg/g of ginsenoside Rg3r, and 88.5mg/g of acid
polysaccharide. The HPLC picture of KRG components
is shown in Figure 1. The placebo group took 2 tablets
that were made from the same corn starch and cellulose
as the KRG tablets in the same shape and size with the
addition of Red Ginseng flavor twice a day. The KRG
and placebo tablets were manufactured and supplied by
the Korea Ginseng Corporation (Seoul, Korea). No other
medication was prescribed, and the patients’ original dia-
betes medication remained unchanged. All subjects, clini-
cal investigators, and outcome assessors were blind to
treatment allocation.
All participants provided informed consent, and the
study was approved by the Institutional Review Board of
Gangnam Severance Hospital. The study was registered on
ISRCTN17039603.
2.2.1. Anthropometric Parameters and Biochemical Profiles.
Body weight and height were measured in the morning with
participants wearing light clothing. Body mass index (BMI)
was calculated as body weight in kilograms divided by height
in meters squared (kg/m2).
Blood samples were taken from the antecubital vein
after at least 8 hours of fasting at weeks 0, 12, and 24.
The fasting plasma glucose concentrations were measured
by a standard glucose oxidase method (747 Automatic
Analyzer, Hitachi, Tokyo, Japan). Fasting serum insulin
was determined by chemiluminescence (RIA Kit, Daiichi,
Japan), and HbA1c was measured by high-performance
liquid chromatography (VARIANT II, Bio-Rad, Hercules,
CA, USA). A standard 75 g oral glucose tolerance test
(OGTT) was also performed, and plasma glucose and
insulin levels were measured in venous blood collected at
0, 60, and 120 minutes after ingestion. Total cholesterol,
high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, and triglycerides were mea-
sured enzymatically using a chemical analyzer (Daiichi,
Hitachi 747, Japan). Apolipoprotein A-1 and apolipopro-
tein B were measured through an immunoturbidimetric
method (Cobas Integra 800 Analyzer; Roche Diagnostics)
using standard procedures.
Serum blood urea nitrogen (BUN) and creatinine (Cr)
levels were measured enzymatically using a chemical ana-
lyzer (AU5800, Beckman Coulter, Inc., Brea, CA, USA).
Serum AST and ALT were measured for the liver function
test (AU5800, Beckman Coulter, Inc., Brea, CA, USA).
2.2.2. Insulin Resistance. Insulin resistance was assessed by the
HOMA equation as follows: HomeostasisModel Assessment
of Insulin Resistance ðHOMA − IRÞ = ½ fasting glucose ðmg/dlÞ
× fasting insulin ðmcIU/mlÞ/405.
2.2.3. Diabetic Neuropathy Assessment. Diabetic peripheral
neuropathy was assessed using the current perception
thresholds (CPT) test by Neurometer® (Neurotron, Inc., Bal-
timore, MD, USA). It was measured at the beginning of the
study (baseline) and after 24 weeks of medication.
The patient was to sit in a comfortable position with two
electrodes coated with conductive gel attached to unilateral
dorsal surfaces of the distal phalanges of the index finger
and great toe. The current was increased (to a maximum of
9.99mA) until the patient began to feel the current at the skin
where the electrodes are attached. The current was then ter-
minated, decreased by 0.08mA, and reapplied. The patient
was tested with three different alternating frequencies of elec-
trical stimulus (2000, 250, and 5Hz). At each frequency, the
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current was slowly increased until the subject first reported
the perception of sensation. The current was then decreased
and reincreased until a consistent threshold is measured [6].
2.2.4. Complication-Related Mediators. The serum levels of
8-epi-PGF2α (Cloud-Clone Corp., CEA749Ge), high-
sensitivity CRP (CusaBio, CSB-E08617h), TNF-α (Cloud-
Clone Corp., SEA133Hu), and AGEs (Cloud-Clone Corp.,
CEB353Ge) were quantified by enzyme-linked immuno-
sorbent assay. Blood samples were centrifuged immediately
(1600 g, 10 minutes), and the serum was stored at -70°C
until analysis. All procedures were performed according
to the manufacturer’s instructions.
2.3. Statistical Analysis. The primary outcomes were changes
of CPT levels at week 24. Secondary outcomes were changes
in fasting plasma glucose, HbA1c, and various metabolic and
inflammatory mediators of diabetic complications at weeks 0
and 24.
Statistical analysis was performed using SPSS version
23.0 for Windows. All data were presented as mean ± SD.
The independent t-test was used to compare changes from
baseline to 24 weeks between the two groups. The paired
t-test was used to compare baseline data with changes at
24 weeks for each group. A value of p < 0:05 was consid-
ered statistically significant.
3. Results
3.1. Patient Characteristics. During the study period, 9
patients dropped out due to a lack of time, lack of compli-
ance, and adverse effects. A total of 61 patients (30 patients
in the KRG group and 31 in the placebo group) completed
the study (Figure 2). The patients’ baseline characteristics
are outlined in Table 1. The participants’ mean age was 59
years, mean BMI was 25 kg/m2, and mean diabetes duration
was 12 years. Approximately one-third of the patients were
taking one type of oral hypoglycemic agent and two-thirds
were taking more than two agents. There were no significant
differences between the two groups in terms of smoking and
alcohol consumption.
3.2. Changes in Metabolic Parameters. There were no differ-
ences in BMI and blood pressure after 24 weeks of
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Figure 1: HPLC picture of KRG ginsenosides. An expanded version of (a) is shown in (b).
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medication. Also, there were no significant differences
regarding HbA1c, fasting plasma glucose, and insulin levels
in both groups. As an index of insulin resistance, HOMA-
IR was elevated after 24 weeks in both the KRG and placebo
groups, but was not statistically significant. Lipid profiles
(total cholesterol, triglyceride, apolipoprotein A1, apolipo-
protein B, HDL, and LDL-cholesterol) also exhibited no sta-
tistically significant changes after 24 weeks of drug
administration (Table 2).
3.3. Changes in CPT and Diabetic Complication-Related
Mediators. CPT was significantly improved in both the left
and right lower extremities at various frequencies in the
KRG group, while most of the CPT did not show statistically
significant improvement in the placebo group (Table 3).
8-epi-PGF2α, advanced glycation end product (AGE),
and inflammatory markers (hsCRP, IL-6, and TNF-α) were
not significantly altered in both the KRG and placebo groups
(Table 3).
3.4. Subgroup Analysis. Subjects were divided into subgroups
according to the duration of diabetes and the presence of dia-
betic microvascular complications.
In subjects with diabetes duration of less than 5 years, fast-
ing insulin decreased from 11:1 ± 4:1 to 6:3 ± 2:1 mcIU/ml,
and HOMA-IR improved significantly from 3:39 ± 1:2 to
A total of 70 patients were enrolled.
Randomization
KRG group (n = 35) Placebo group (n = 35)
Completed 24 wks (n = 30) Completed 24 wks (n = 31)
Drop out
AE (n = 1)
Drop out
AE (n = 2)SAE (n = 2)
Patient’s refusal ( n = 2)
(i)
(ii) (i)(ii)(iii) Patient’s refusal ( n = 2)
Figure 2: Trial flow.
Table 1: Subject characteristics at baseline.
KRG group (n = 30) Placebo group (n = 31) p valuea
Gender (M/F) 17/13 19/12 NSa
Age (years) 59:3 ± 8:79 59:7 ± 7:22 NS
BMI (kg/m2) 24:7 ± 2:93 24:8 ± 2:82 NS
DM duration (years) 11:6 ± 6:80 12:6 ± 8:83 NS
DM medication
Monotherapy 9 (30.0%) 11 (35.5%)
Dual therapy 13 (43.3%) 8 (25.8%) NSb
Triple therapy 18 (26.7%) 12 (38.7%)
SBP (mmHg) 131:6 ± 15:64 132:2 ± 16:77 NS
DBP (mmHg) 77:7 ± 8:71 80:8 ± 12:03 NS
Smoking
Nonsmoker 16 (53.3%) 20 (64.5%)
Ex-smoker 3 (10.0%) 5 (16.1%) NSb
Current smoker 11 (36.7%) 6 (19.4%)
Alcohol
No 22 (73.3%) 22 (71.0%)
NSb
Yes 8 (26.7%) 9 (29.0%)
Data are presented asmean ± SD. aAnalyzed by independent t-tests and the p value represents the comparison to the placebo group. bAnalyzed by Chi-square.
KRG: Korean Red Ginseng; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.
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2:08 ± 0:8 after KRG treatment (p = 0:044 and p = 0:046,
respectively). In the patients with diabetes duration of more
than 5 years, the CPT of lower extremities were significantly
improved after KRG administration from 299:42 ± 81 to
258:92 ± 86 at 2000Hz (p = 0:012) and from 137:13 ± 43 to
106:96 ± 36 at 250Hz (p = 0:002), while there were no signif-
icant changes in the placebo group.
In patients who already had abnormal CPT at baseline,
the CPT levels at 2000Hz decreased significantly from
323:24 ± 91 to 278:94 ± 93 (p = 0:049), and the CPT levels at
250Hz decreased significantly from 145:65 ± 46 to 119:35 ±
36 (p = 0:028) after KRG administration. These changes were
not observed in the placebo group.
3.5. Safety. There were no serious adverse effects in both the
KRG and placebo groups. Three patients in the KRG group
dropped out due to fever and gastrointestinal disturbance,
foot pain, and deterioration of blood glucose. In the placebo
Table 2: Anthropometric and biochemical profile.
KRG group (n = 30) Placebo group (n = 31)
Week 0 Week 24 Within-group p value Week 0 Week 24 Within-group p value
BMI (kg/m2) 24:8 ± 2:96 24:5 ± 2:75 NS 24:4 ± 2:68 24:2 ± 2:76 NS
SBP (mmHg) 132 ± 15:91 133 ± 15:21 NS 132 ± 16:88 130 ± 19:18 NS
DBP (mmHg) 78 ± 8:77 80 ± 9:13 NS 80 ± 12:11 79 ± 13:84 NS
HbA1c (%) 7:4 ± 0:79 7:5 ± 0:83 NS 7:4 ± 0:70 7:7 ± 0:85 NS
FPG (mg/dl) 143 ± 30:41 150 ± 31:98 NS 153 ± 30:09 159 ± 39:33 NS
2 h Glc (mg/dl) 305 ± 65:31 307 ± 74:60 NS 301 ± 67:49 306 ± 79:25 NS
Ins (mcIU/ml) 7:6 ± 4:51 7:3 ± 4:34 NS 7:8 ± 5:08 7:8 ± 5:12 NS
2 h Ins (mcIU/ml) 31:6 ± 17:93 31:6 ± 20:03 NS 32:1 ± 23:53 29:4 ± 21:12 NS
HOMA-IR 2:6 ± 1:71 2:7 ± 1:84 NS 2:9 ± 1:80 3:1 ± 2:42 NS
TC (mg/dl) 171 ± 36:14 179 ± 41:51 NS 170 ± 33:64 180 ± 39:62 NS
TG (mg/dl) 167 ± 130:82 160 ± 93:52 NS 141 ± 60:90 182 ± 177:19 NS
HDL-C (mg/dl) 48 ± 10:44 49 ± 8:65 NS 50 ± 9:56 50 ± 11:16 NS
LDL-C (mg/dl) 114 ± 28:80 119 ± 34:27 NS 113 ± 29:35 117 ± 30:75 NS
Apo A1 (mg/dl) 139:3 ± 17:88 140:0 ± 17:66 NS 146:8 ± 20:34 145:3 ± 22:87 NS
Apo B (mg/dl) 89:6 ± 19:29 95:6 ± 25:84 NS 90:4 ± 21:49 95:2 ± 22:53 NS
BMI: bodymass index; SBP: systemic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; 2 h Glc: 2-hour glucose; Ins: fasting insulin; 2 h
Ins: 2-hour insulin; TC: total cholesterol; TG: triglyceride; HDL-C: HDL-cholesterol; LDL-C: LDL-cholesterol; Apo A1: apolipoprotein A1; Apo B:
apolipoprotein B.
Table 3: Diabetic microvascular complication studies.
KRG group (n = 30) Placebo group (n = 31)
Week 0 Week 24 Within-group p value Week 0 Week 24 Within-group p value
CPT of Lex, right
2000Hz 306:07 ± 82 266:79 ± 81 0.010∗ 295:54 ± 87 256:79 ± 80 NS
250Hz 135:64 ± 40 110:07 ± 36 0.007∗ 140:68 ± 55 118:93 ± 35 NS
5Hz 88:61 ± 38 76:07 ± 25 NS 93:11 ± 33 82:79 ± 33 NS
CPT of Lex, left
2000Hz 300:79 ± 82 267:14 ± 82 0.023∗ 288:86 ± 93 266:86 ± 72 NS
250Hz 130:07 ± 40 105:18 ± 35 0.005∗ 137:29 ± 67 107:39 ± 35 0.022∗
5Hz 85:54 ± 25 69:04 ± 23 0.007∗ 91:71 ± 35 70:96 ± 27 0.004∗
PGF2α (pg/ml) 132:48 ± 109:50 125:89 ± 110:00 NS 151:34 ± 143:06 137:73 ± 122:23 NS
hsCRP (mcg/ml) 2:55 ± 7:47 0:61 ± 0:26 NS 1:56 ± 2:51 1:04 ± 1:73 NS
IL-6 (pg/ml) 2:90 ± 6:21 2:09 ± 1:75 NS 1:86 ± 1:48 1:83 ± 1:57 NS
TNF-α (pg/ml) 10:70 ± 20:82 14:73 ± 34:26 NS 3:11 ± 4:41 2:96 ± 4:33 NS
AGE (mcg/ml) 2:01 ± 1:06 2:11 ± 1:03 NS 1:89 ± 0:96 1:93 ± 0:94 NS
∗p ≤ 0:05 is significant. CPT: current perception threshold; Lex: lower extremities; PGF2α: isoprostane 8-epi PGF2α; hsCRP: high-sensitivity C-reactive protein;
IL-6: interleukin 6; TNF-α: TNF-alpha; AGE: advanced glycation end product.
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group, two patients dropped out due to fever, palpitations,
and fatigue. Serum AST and ALT levels did not deteriorate,
and hypoglycemia did not occur during the study period in
both groups.
4. Discussion
In this study, we investigated the effects of KRG on diabetic
neuropathy in Type 2 diabetes patients. KRG is a Korean tra-
ditional herb that is becoming popular worldwide for its ben-
eficial effects in obesity, insulin resistance, dyslipidemia, and
cardiovascular diseases due to its antioxidant and anti-
inflammatory effects. Many diabetes patients take KRG for
the above reasons. However, there has been no study that
investigated its effect on diabetic neuropathy, which is the
most common diabetic microvascular complication that does
not have a definite pathogenic treatment option.
Twenty-four weeks of KRG administration resulted in
improved peripheral neuropathy particularly in those with
a longer diabetes duration and underlying neuropathy.
Meanwhile, insulin sensitivity improved in those with a rela-
tively short diabetes duration. We believe our study results
have significance for its possible beneficial effects in diabetic
neuropathy without serious adverse events.
Diabetic neuropathy is the most common diabetic
chronic complication that results in pain, disability, and
amputation. Its pathogenesis is not fully understood yet,
but toxic effects of chronic hyperglycemia involving oxidative
stress, polyol pathway, and advanced glycation end products
(AGE) are known to play important roles [21–25]. Ginseng
has been shown to have antioxidant and anti-inflammatory
properties, and thus studies have been conducted to assess
the effects of ginseng on diabetic microvascular complica-
tions including neuropathy, retinopathy, and nephropathy
in diabetic animal models [26, 27]. However, there has been
no human study so far.
In this study, the CPT test, which is a quick, convenient,
but also a reliable way to assess diabetic neuropathy was used
[28]. The KRG group showed consistent and statistically sig-
nificant improvements of CPT levels throughout different
frequencies of stimulus. Meanwhile, the placebo group also
showed improved CPT, but mostly it did not reach statistical
significance. In particular, CPT levels at higher frequencies
were significantly improved in the KRG group. The CPT
levels at 2000 or 250Hz are more clinically important than
those at 5Hz, because it has been shown that the Neuro-
meter® displays poor reproducibility at low frequencies like
5Hz compared to 250 and 2000Hz [29]. Also, it was notable
that CPT was significantly improved in patients with longer
diabetes duration and in those who already had an impaired
CPT at baseline.
We have assessed various factors known to mediate
chronic diabetic complications to investigate possible mech-
anisms for such improvement. We investigated AGE and
various oxidative and inflammatory markers such as high-
sensitivity C-reactive protein, interleukin 6, TNF-α, and 8-
epi-PGF2α. However, they were not altered after 24 weeks
of KRG and did not show significant correlations with
changes in CPT. There have been many studies assessing
the effects of natural compounds with antioxidant or
anti-inflammatory effects on diabetic complications, and
many showed benefits. For example, an animal study con-
ducted on streptozotocin-induced diabetes mice demon-
strated a decreased AGE level in urine and kidney as well
as plasma TNF-α and reduced renal damage after KRG
administration [16].
However, like our study, most of the human studies con-
ducted with natural compounds on diabetic neuropathy
failed to elucidate the underlying mechanism [26]. First of
all, compared to diabetic nephropathy, it is harder to assess
diabetic neuropathy and its mechanism is more complex.
Also, in contrast to pharmacologically manufactured prod-
ucts with high potency and predictable pharmacodynamics,
natural compounds like KRG tend to have diverse pleiotropic
effects rather than one strong specific effect. Therefore,
although their properties can be observed in in vivo experi-
ments, it may be too moderate to be seen at the human blood
level. In other words, the effect of KRG on neuropathy may
have resulted not from one strong mechanism but rather
from multiple mechanisms that interact with each other.
There have been inconsistent data for the effects of KRG
on blood glucose control, insulin resistance, and various met-
abolic parameters. In this study, the administration of KRG
for 24 weeks did not affect patient BMI, blood pressure, and
blood glucose. Regarding insulin resistance, changes in fast-
ing insulin and HOMA-IR were not significantly different
between the two groups. However, in the subgroup analysis
with patients whose duration of diabetes mellitus was rel-
atively short (less than 5 years), fasting insulin significantly
decreased from 11.1 to 6.3mcIU/ml and HOMA-IR signif-
icantly improved from 3.39 to 2.08 (p = 0:044 and p =
0:046, respectively). These results are in line with previous
studies that KRG improves peripheral insulin resistance
[10, 14, 30, 31].
In terms of safety, there was no hepatotoxicity, nephro-
toxicity, or hypoglycemia in the KRG group. Among the 3
patients in the KRG group who dropped out due to adverse
effects, one was admitted to the hospital due to deterioration
in blood glucose level. However, this was because the patient
did not properly take the prescribed antidiabetic drugs and
had an uncontrolled diet. Another patient in the KRG group
complained of fever and gastrointestinal disturbance, but
there was one patient with similar symptoms in the placebo
group. The third patient complained of foot pain, but there
was no sign of diabetic foot. In the placebo group, one patient
dropped out due to fever and fatigue, while another patient
exhibited elevated liver enzymes.
There are several limitations to this study. First of all, the
number of study subjects was small, and the study duration
was relatively short to assess chronic diabetic complications.
However, this was the first randomized controlled trial to
assess the effects of KRG on diabetic neuropathy in Type 2
diabetes patients. Secondly, the underlying mechanism for
improved CPT and insulin resistance following KRG admin-
istration had not been elucidated. Thirdly, there is no data
after the discontinuation of KRG to examine the reversal
effect. Also, all the subjects took the same dose of KRG, which
is the commercially available dose in Korea, regardless of
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their body weight. This study would have observed more pre-
cise KRG effects if the dose was titrated to body weight.
Lastly, subjects with renal or hepatic dysfunction were
excluded from the study, and therefore, the effects and safety
of KRG cannot be generalized.
In conclusion, in this first randomized controlled trial to
assess the effects of KRG on chronic diabetic neuropathy, a
24-week administration of KRG significantly improved
markers of diabetic neuropathy especially in those who
already had neuropathy or a long diabetes duration. In addi-
tion, it also improved insulin resistance in patients with a
short diabetes duration. Considering that diabetic microvas-
cular complication is a chronic progressive disease, a further,
larger population study with a longer follow-up period is
warranted to verify and understand the effects of KRG on
diabetic complications.
Abbreviations
AGE: Advanced glycation end products
CPT: Current perception threshold
KRG: Korean Red Ginseng.
Data Availability
The data used to support the findings of this study are avail-
able from the corresponding author upon request.
Disclosure
The abstract was presented at the 48th EASD Annual Meet-
ing of the European Association for the Study of Diabetes.
Conflicts of Interest
The authors declare no conflicts of interest.
Authors’ Contributions
K.P. researched data and wrote the manuscript. J.K. contrib-
uted to collecting data. C.W.A., S.K., J.S.P., and Y.K. contrib-
uted to interpreting the findings and editing the manuscript.
J.S.N. is the guarantor of this work and, as such, had full
access to all the data in the study and takes responsibility
for the integrity of the data and the accuracy of the data
analysis.
Acknowledgments
This study was financially supported by the Korea Ginseng
Corporation.
References
[1] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global
prevalence of diabetes: estimates for the year 2000 and projec-
tions for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053,
2004.
[2] A. J. Boulton, A. I. Vinik, J. C. Arezzo et al., “Diabetic neurop-
athies: a statement by the American Diabetes Association,”
Diabetes Care, vol. 28, no. 4, pp. 956–962, 2005.
[3] J. C. Won, H. S. Kwon, C. H. Kim et al., “Prevalence and clin-
ical characteristics of diabetic peripheral neuropathy in hospi-
tal patients with type 2 diabetes in Korea,” Diabetic Medicine,
vol. 29, no. 9, pp. e290–e296, 2012.
[4] M. Yorek, R. A. Malik, N. A. Calcutt, A. Vinik, and
S. Yagihashi, “Diabetic neuropathy: new insights to early diag-
nosis and treatments,” Journal Diabetes Research, vol. 2018,
article 5378439, 3 pages, 2018.
[5] J. H. Park and J. C. Won, “Patterns of nerve conduction abnor-
malities in patients with type 2 diabetes mellitus according to
the clinical phenotype determined by the current perception
threshold,” Diabetes and Metabolism Journal, vol. 42, no. 6,
pp. 519–528, 2018.
[6] G. V. Inceu and I. A. Veresiu, “Measurement of current per-
ception thresholds using the Neurometer®—applicability in
diabetic neuropathy,” Medicine and Pharmacy Reports,
vol. 88, no. 4, pp. 449–452, 2015.
[7] R. Matsutomo, K. Takebayashi, and Y. Aso, “Assessment of
peripheral neuropathy using measurement of the current per-
ception threshold with the neurometer in patients with type 2
diabetes mellitus,” The Journal of International Medical
Research, vol. 33, no. 4, pp. 442–453, 2005.
[8] H. Garcia-Alcala, C. I. Santos Vichido, S. Islas Macedo et al.,
“Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Dia-
betic Patients with Symptomatic Polyneuropathy Who
Responded to Initial 4-Week High-Dose Loading,” Journal
Diabetes Research, vol. 2015, article 189857, 8 pages, 2015.
[9] A. Mimenza Alvarado and S. Aguilar Navarro, “Clinical trial
assessing the efficacy of gabapentin plus B complex (B1/B12)
versus pregabalin for treating painful diabetic neuropathy,”
Journal Diabetes Research, vol. 2016, article 4078695, 8 pages,
2016.
[10] H. Lee, J. Choi, S. S. Shin, and M. Yoon, “Effects of Korean red
ginseng (Panax ginseng) on obesity and adipose inflammation
in ovariectomized mice,” Journal of Ethnopharmacology,
vol. 178, pp. 229–237, 2016.
[11] S. Y. Kim, S. K. Seo, Y. M. Choi et al., “Effects of red ginseng
supplementation on menopausal symptoms and cardiovascu-
lar risk factors in postmenopausal women: a double-blind ran-
domized controlled trial,” Menopause, vol. 19, no. 4, pp. 461–
466, 2012.
[12] M. S. Lee, M. S. Lee, H. J. Lim, and S. R. Moon, “Survey of the
use of complementary and alternative medicine among
Korean diabetes mellitus patients,” Pharmacoepidemiology
and Drug Safety, vol. 13, no. 3, pp. 167–171, 2004.
[13] M. R. Oh, S. H. Park, S. Y. Kim et al., “Postprandial
glucose-lowering effects of fermented red ginseng in subjects
with impaired fasting glucose or type 2 diabetes: a random-
ized, double-blind, placebo-controlled clinical trial,” BMC
Complementary and Alternative Medicine, vol. 14, no. 1,
p. 237, 2014.
[14] V. Vuksan, M. K. Sung, J. L. Sievenpiper et al., “Korean red
ginseng (Panax ginseng) improves glucose and insulin regula-
tion in well-controlled, type 2 diabetes: Results of a random-
ized, double-blind, placebo-controlled study of efficacy and
safety,” Nutrition, Metabolism, and Cardiovascular Diseases,
vol. 18, no. 1, pp. 46–56, 2008.
[15] J. Y. Kim, J. Y. Park, H. J. Kang, O. Y. Kim, and J. H. Lee, “Ben-
eficial effects of Korean red ginseng on lymphocyte DNA
7Journal of Diabetes Research
damage, antioxidant enzyme activity, and LDL oxidation in
healthy participants: a randomized, double-blind, placebo-
controlled trial,” Nutrition Journal, vol. 11, no. 1, p. 47, 2012.
[16] S. K. Seo, Y. Hong, B. H. Yun et al., “Antioxidative effects of
Korean red ginseng in postmenopausal women: a double-
blind randomized controlled trial,” Journal of Ethnopharma-
cology, vol. 154, no. 3, pp. 753–757, 2014.
[17] Y. Y. Lee, E. Saba, M. Irfan et al., “The anti-inflammatory and
anti-nociceptive effects of Korean black ginseng,” Phytomedi-
cine, vol. 54, pp. 169–181, 2019.
[18] J. Y. Ban, S. W. Kang, J. S. Lee, J. H. Chung, Y. G. Ko, and
H. S. Choi, “Korean red ginseng protects against neuronal
damage induced by transient focal ischemia in rats,” Exper-
imental and Therapeutic Medicine, vol. 3, no. 4, pp. 693–
698, 2012.
[19] H. Y. Quan, D. Y. Kim, and S. H. Chung, “Korean red ginseng
extract alleviates advanced glycation end product-mediated
renal injury,” Journal of Ginseng Research, vol. 37, no. 2,
pp. 187–193, 2013.
[20] S. Sen, S. Chen, Y. Wu, B. Feng, E. K. Lui, and S. Chakrabarti,
“Preventive effects of North American ginseng (Panax quin-
quefolius) on diabetic retinopathy and cardiomyopathy,” Phy-
totherapy Research, vol. 27, no. 2, pp. 290–298, 2013.
[21] C. Ferri, G. Croce, V. Cofini et al., “C-reactive protein: interac-
tion with the vascular endothelium and possible role in human
atherosclerosis,” Current Pharmaceutical Design, vol. 13,
no. 16, pp. 1631–1645, 2007.
[22] Y. Mugabo, L. Li, and G. Renier, “The connection between C-
reactive protein (CRP) and diabetic vasculopathy. Focus on
preclinical findings,” Current Diabetes Reviews, vol. 6, no. 1,
pp. 27–34, 2010.
[23] D. M. Niedowicz and D. L. Daleke, “The role of oxidative stress
in diabetic complications,” Cell Biochemistry and Biophysics,
vol. 43, no. 2, pp. 289–330, 2005.
[24] V. P. Singh, A. Bali, N. Singh, and A. S. Jaggi, “Advanced gly-
cation end products and diabetic complications,” The Korean
Journal of Physiology & Pharmacology, vol. 18, no. 1, pp. 1–
14, 2014.
[25] A. K. Schreiber, C. F. Nones, R. C. Reis, J. G. Chichorro, and
J. M. Cunha, “Diabetic neuropathic pain: physiopathology and
treatment,” World Journal of Diabetes, vol. 6, no. 3, pp. 432–
444, 2015.
[26] M. Galuppo, S. Giacoppo, P. Bramanti, and E. Mazzon, “Use of
natural compounds in the management of diabetic peripheral
neuropathy,” Molecules, vol. 19, no. 3, pp. 2877–2895, 2014.
[27] L. He, H. Wang, C. Gu, X. He, L. Zhao, and X. Tong, “Admin-
istration of traditional Chinese blood circulation activating
drugs for microvascular complications in patients with type 2
diabetes mellitus,” Journal Diabetes Research, vol. 2016, article
1081657, 9 pages, 2016.
[28] K. S. Park, Y. C. Kwon, M. Youn, Y.-S. Park, Y.-H. Hong, and
J.-J. Sung, “Current perception threshold in diabetic sensory
polyneuropathy with normal routine nerve conduction study,”
Annals of Clinical Neurophysiology, vol. 19, no. 2, pp. 125–130,
2017.
[29] B. C. Tsui, T. J. Shakespeare, D. H. Leung, J. H. Tsui, and G. N.
Corry, “Reproducibility of current perception threshold with
the Neurometer® vs the Stimpod NMS450 peripheral nerve
stimulator in healthy volunteers: an observational study,”
Canadian Journal of Anaesthesia, vol. 60, no. 8, pp. 753–760,
2013.
[30] J. M. Cheon, D. I. Kim, and K. S. Kim, “Insulin sensitivity
improvement of fermented Korean Red Ginseng (Panax gin-
seng) mediated by insulin resistance hallmarks in old-aged
ob/ob mice,” Journal of Ginseng Research, vol. 39, no. 4,
pp. 331–337, 2015.
[31] S. H. Lee, H. J. Lee, Y. H. Lee et al., “Korean red ginseng (Panax
ginseng) improves insulin sensitivity in high fat fed Sprague-
Dawley rats,” Phytotherapy Research, vol. 26, no. 1, pp. 142–
147, 2012.
8 Journal of Diabetes Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
